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Executive Summary 
 
This paper examines some of the costs associated with the design of the Medicare drug benefit using 
the “doughnut hole” gap in coverage as a yardstick with which to assess these costs. It notes that: 
 
•  The Congressional Budget Office’s projection of the higher administrative costs that result from 
having the plan administered through private insurers, instead of the existing Medicare system, is 
almost one-fourth as large as the doughnut hole. This implies that if the benefit had been 
administered through the existing Medicare system, then the doughnut hole could be 
considerably smaller at no additional cost to the government.  
 
•  If Medicare had been allowed to bargain directly with the pharmaceutical industry, and could 
obtain prices as low as the Australian government does, the savings would be more than twice 
the size of the doughnut hole. This would allow for elimination of the doughnut hole, in addition 
to substantial savings for the federal and state governments. 
 
•  A survey by the Medicare Payment Advisory Council found that the typical beneficiary spent 
more than 8 hours deciding among the competing plans being offered under the program. The 
implicit cost of this time is equal to approximately 40 percent of the size of the doughnut hole. 
 
•  A survey by a consulting firm found that primary care physicians claimed that they were spending 
an hour and half daily counseling patients on the benefit. While this figure is far too high to be 
plausible, it does indicate that doctors perceive the benefit as imposing a substantial burden on 
their time. The time required of doctors, pharmacists and other health care providers because of 
the unnecessary complexity of the plan is likely to be substantial and should be included in any 
comprehensive assessment of the benefit in its current design. 
 
It is clear that the specific design of the 2003 bill added substantially to the benefit’s cost and 
complexity. It will be important to assess these costs through time in order to find ways in which the 
bill can be redesigned to be more efficient.   
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Introduction 
 
This summer and fall, millions of senior citizens and disabled Americans enrolled in Medicare Part 
D drug plans will discover first hand the “doughnut hole,” the unusual $2,850 gap in coverage that 
was placed into the plan to save the government money. This doughnut hole is peculiar because it 
goes directly against the general design of insurance. Usually insurance policies are designed to 
protect holders against large losses. Policies typically have deductibles and/or co-pays with the 
assumption that most people can afford modest costs. After a certain level of costs, typically the 
share born by the insurer increases – this is the bad event against which the policy holder is insuring 
themselves. 
 
FIGURE 1.   Per Person Drug Expenditures Under Medicare Drug Plan 
 
 
Source: Author’s calculations: see text 
 
The Medicare drug benefit effectively takes the opposite approach. There is an initial deductible, and 
the basic formula provides for a 25 percent co-payment, but the benefits continue only until the 
beneficiary incurs $2,250 in drug expenses for the year. At that point the beneficiary is directly liable 
for the next $2,850 in annual expenditures, with no assistance provided through the benefit. Only if 
expenses exceed $5,100 for the year will the insurance again provide benefits, at that point paying 95 
percent of expenses in excess of $5,100.  
 
The size of this doughnut hole will grow in the future, since the basic benefit schedule is indexed to 
average per person drug spending, which is projected to grow at a rate of more than 8 percent 
annually. This means that the spending cutoff that places people in the doughnut hole will be 8 
percent higher next year (approximately $2,430), but the point at which coverage kicks back in will 
also be 8 percent higher (approximately $5,508). This would leave a gap, where seniors could 
potentially spend $3,078 on prescription drugs, without receiving any assistance from their Part D 
insurance. (It is worth noting that beneficiaries are still required to pay the monthly insurance 
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size of the doughnut hole expanding to more than $6,100 in 2016 (see Figure 1). While the Part D 
benefit will still pay on average the same percentage of beneficiaries’ drugs, with drug prices 
projected to rise rapidly relative to income growth, the gap in coverage will be far larger relative to 
projected income in the future than it is today.
1
 
This peculiar design was adopted in order to limit the cost of the Medicare drug benefit. Of course, 
there were other ways in which costs could have been contained. For example, the Congressional 
Budget Office estimated that the decision to have the program administered through private insurers 
rather than the existing Medicare program added nearly $5 billion a year to the program’s expenses. 
In addition, the provision to prohibit Medicare from bargaining directly with the drug companies for 
lower prices, as is done by the Veterans Administration and other governments, may have added 
more than $40 billion to the annual cost of the program in its first years.
2 This paper compares the 
size of the savings from the doughnut hole with various sources of waste that resulted from the 
design of the Medicare drug benefit.  
                                                 
 
1 See Baker, D. 2003. “Still a Pain: The Cost of Prescription Drugs to Seniors With the Medicare Drug Benefit.” 
Washington, DC: Center for Economic and Policy Research 
[http://www.cepr.net/publications/medicare_drug_benefit.pdf]. 
2 See Baker, D. 2006. “The Savings From an Efficient Medicare Drug Plan,” Washington, DC: Center for Economic and 
Policy Research [http://www.cepr.net/publications/efficient_medicare_2006_01.pdf]. The additional cost that results 
from the prohibition on bargaining is projected to rise to more than $100 billion annually by 2012.  
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The Size of the Doughnut Hole 
 
While the doughnut hole will grow through time as drug costs rise, the savings to the government 
from the doughnut hole are limited. Table 1 shows the percentage of beneficiaries projected to reach 
various spending levels for prescription drugs in 2006. 
 
  
Based on this projected distribution of spending, it is possible to calculate the amount of drug 
spending that will fall into the doughnut hole. Table 2 shows the amount of expenditures for each 
spending bracket that will fall into the doughnut hole. The calculations assume that average 
spending in each bracket is the mid-point on the bracket. 
 
The calculations in Table 2 show the size of the doughnut hole based on 2006 levels of drug 
expenditures would be approximately $20.5 billion, if all beneficiaries were enrolled in the program 
from January 1. Since many beneficiaries did not enroll in Part D until April or May, the number of 
people and the amount of expenditures that fall into the doughnut hole in 2006 will be substantially 
less than is indicated by the calculations in Table 2. 
 
However, these calculations still provide a useful point of reference. In 2007, when the vast majority 
of beneficiaries will be enrolled in the program for the whole year, the calculations in Table 2 should 
give a reasonable approximation of the amount of expenditures that will fall into the doughnut hole, 
with the qualification that average per person drug expenditures are projected to be approximately 
8.0 percent higher than in 2006. Given the program’s formulas, the size of the doughnut hole will 
rise through time at the same rate as the increase in the cost of drugs per beneficiary, or 8 percent 
annually, as projected by the Congressional Budget Office. 
TABLE 1
Spending levels Percent of Beneficiaries
$0 -$1,080    35.0%
$1,080 - $2,160 17.0%
$2,160 - $3,240 13.7%
$3,240 - $4,320 9.2%
$4,320 - $5,400 7.2%
$5,400 - $6,480 4.9%
$6,480 - $7,560 3.1%
$7,560 - $8,640 2.4%
$8,640 - $9,720 1.4%
$9,720 -$10,800 1.2%
Over $10,800 4.3%
Source: Congressional Budget Office.
Projected 2006 Spending on Prescription Drugs by 
Medicare Beneficiaries
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TABLE 2
$0 -$1,080    $0 11.2 $0
$1,080 - $2,160 $0 5.3 $0
$2,160 - $3,240 $308 4.3 $1.30
$3,240 - $4,320 $1,118 2.9 $3.30
$4,320 - $5,400 $1,928 2.3 $4.40
$5,400 - $6,480 $2,138 1.5 $3.30
$6,480 - $7,560 $2,138 1 $2.10
$7,560 - $8,640 $2,138 0.8 $1.60
$8,640 - $9,720 $2,138 0.4 $0.90
$9,720 -$10,800 $2,138 0.4 $0.80
Over $10,800 $2,138 1.4 $2.90
Total $20.5
Source: Congressional Budget Office and author’s calculations. 
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Unnecessary Costs of the Drug Benefit 
 
There are several sources of unnecessary costs associated with the specific design of the Medicare 
Modernization Act of 2003. Two sources of higher costs have received considerable attention: the 
additional administrative costs incurred as a result of providing the benefit through private insurers 
rather than the existing Medicare system, and the higher cost of drugs due to the prohibition against 
Medicare bargaining directly with drug companies for lower prices. The law imposes other costs that 
are more difficult to document, but may nonetheless be substantial.  One of the most obvious of 
these is the cost imposed on beneficiaries, in the form of time spent analyzing various policy options 
as a result of the excessive complexity of the system. This cost is also imposed on health care 
providers and pharmacists as they assist beneficiaries in navigating the system. This section will 
assess the size of these costs in comparison to the size of the doughnut hole. 
 
FIGURE 2.   The Relative Size of the Doughnut Hole and Sources of Waste in the MMA 
 
Source: Congressional Budget Office and author’s calculations 
 
It is relatively simple to obtain estimates of the additional costs associated with the decision to offer 
the benefit through private insurers instead of the existing Medicare system. The Congressional 
Budget Office projected that additional administrative costs due to the marketing expenses and 
profits of the private insurers would be approximately $4.6 billion in the first year for which the 
program was in operation.
3 It is also possible to calculate the potential savings to the beneficiaries 
and the government if Medicare had been allowed to use its bargaining power to negotiate drug 
























                                                 
 
3 This projection appears in CBO, 2004. “A Detailed Description of CBO's Cost Estimate for the Medicare Prescription 
Drug Benefit.” Washington, DC: Congressional Budget Office, p 17 
[http://www.cbo.gov/showdoc.cfm?index=5668&sequence=0].  
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the Australian government, it would have reduced projected drug expenditures by approximately $42 
billion in 2006.
4    
 
Figure 2 shows the size of the doughnut hole in 2006, relative to the additional administrative costs 
attributable to the decision to provide the benefit through private insurers, as well as the potential 
savings from having Medicare act as a bulk buyer of drugs. As can be seen, the additional 
administrative expenses that result from using private insurers are equal to almost one-fourth of the 
size of the doughnut hole. This means that if the program had taken advantage of Medicare efficient 
administrative structure, the doughnut hole would be considerably smaller. The last bar shows that 
the potential savings from having Medicare negotiate directly with drug industry are more than twice 
the size of the doughnut hole. In other words, if Congress had allowed Medicare to negotiate 
directly with the drug industry, it would have been possible eliminate the doughnut hole altogether, 
and still have savings left over to reduce the costs to the federal and state governments. 
 
                                                 
 
4 The derivation of this calculation is explained in Baker, 2006.  
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Other Costs of Administrative Complexity 
 
It is more difficult to quantify the costs to beneficiaries and providers of the additional complexity 
resulting from the decision to provide the drug benefit through private insurers, but it is possible to 
calculate the general order of magnitude of these costs. In the case of the cost incurred by 
beneficiaries as a result of the time required to select among competing plans, a survey by the 
Medicare Payment Advisory Commission found that more than half of the people who had signed 
up for a plan (the survey was conducted in February and March of 2006) had spent more than 8 
hours examining their options.
5
 
Assigning the economy-wide average hourly compensation for workers as the value of this time to 
beneficiaries implies that the cost of this selection averaged $240 for the beneficiaries who went 
through this process.
6 This cost is substantial relative to the size of the doughnut hole.  
 
FIGURE 3.   The Per Person Cost of the Doughnut Hole and Time Spent Choosing Plans 
 
 
Source: Congressional Budget Office, Medicare Payment Advisory Commission, and author’s 
calculations 
 
Figure 3 shows the average size of the doughnut hole ($640 per beneficiary) compared to the cost of 
the time spent choosing plans. It is understandable that many seniors would have viewed this 
expenditure of time as a substantial and unnecessary burden. In principle, this will be a one-time 
expenditure of time, since most seniors will probably opt to remain with the plan they have chosen. 









"Doughnut hole" Time Spent Selecting Plans
                                                 
 
5  See Medicare Payment Advisory Council, 2006. “How Beneficiaries Learned About the Drug Benefit and Made Plan 
Choices,” Table 8-4, [http://www.medpac.gov/publications/congressional_reports/Jun06_Ch08.pdf]. 
6 This calculation assumes an average hourly compensation of $30. This is derived from the $26.60 average hourly 
compensation for all workers shown in Mishel, Bernstein and Allegretto, 2005, Table 2-2, adjusted upward by 12.6 
percent for the inflation in the years from 2002-2006.  
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may make their current plans less desirable. It may also be the case that some insurers may opt to 
leave the market, as happened with the Medicare Plus Choice program. In such circumstances, 
beneficiaries will be forced to go through the process of selecting a plan again.  
 
The fourth source of costs incurred by the decision to have the drug benefit administered through 
private insurers is the additional time spent by doctors and other health care providers in helping 
beneficiaries navigate the system. No reliable data exists yet to measure how much time the benefit 
is actually requiring from providers, but there is some anecdotal evidence suggesting that the cost is 
substantial. For example, a survey by the J. Scott Group found that the average primary care 
physician was spending 1.5 hours a day communicating with patients about the Part D benefit.
7 
While this figure is far too large to be plausible, it does indicate that physicians perceive the benefit 
as being a substantial imposition on their time. Even if the burden were just 1.5 hours per week, it 
would still impose costs in terms of physicians’ time of more than $1 billion a year.
8
 
Of course, even the simplest benefit would require some amount of time from doctors, as they 
would still be required to consider cost as a factor in choosing medicines. But, this time would be far 
less if there were just a single set of prices and rules. Also, if Medicare had bargained drug prices 
down closer to their production costs, price differences would usually not be large. This would allow 
doctors to make their prescription decisions based primarily on their assessment of the best drug for 
their patients. 
 
In addition to the demands on doctors’ time, the complexity of the plan is also placing a large 
burden on pharmacists. They have had learn the rules for the various plans that are part of the 
Medicare program. Pharmacists have also had to deal with the slip-ups with the system, which have 
often left people without proper coverage. In these cases, pharmacists have frequently opted to still 
provide drugs to customers in the hope of getting payment later, rather than sending Medicare 
beneficiaries home without necessary medication. Such situations have both involved large amounts 
of time, and also exposed pharmacies to financial risk. 
 
A full assessment of the cost of the Medicare Modernization Act would have to include these costs 
and other costs that have been imposed on providers due to its complexity. While providers may 
initially absorb many of these costs, over the long-term, they will be passed on to consumers. If 
doctors find that they have less time to treat patients because of the complexity of the paper work 
associated with the Medicare drug plan, they will end up charging higher fees for their time with 
patients. Similarly, if the complexity of the plan forces doctors offices, hospitals, and pharmacies to 
hire more office staff, then this cost will also be passed on in higher prices. It is too early to know 
whether the problems encountered thus far are simply a result of the initial confusion associated 
with the introduction of the benefit, or whether they are intrinsic to the structure of the new plan. In 
either case, these costs are likely to be large relative to the cost of the program and must be 
considered in a full assessment of its impact.  
 
 
                                                 
 
7 These results are reported on PharmaLive.com, June 8, 2006 
[http://www.pharmalive.com/News/index.cfm?articleid=348220]. In addition, the survey found that their staff was 
fielding an additional 5 calls per day. 
8 If hourly compensation averages $80, this implies a time burden of $6,000 per year, per physician.  
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Conclusion 
 
The peculiar features of the Medicare Modernization Act have imposed large costs on seniors, 
people with disabilities, the government, and health care providers. Specifically, the rule that 
prohibits Medicare from establishing its own plan, and negotiating price discounts directly with the 
pharmaceutical industry, has added hundreds of billions of dollars to the cost of the program over 
its first decade.  
 
In addition, the decision to only provide the benefit through private insurers substantially increased 
both the cost and complexity of the program. The direct administrative costs are readily measured, 
with the Congressional Budget Office projecting the size to be almost one fourth as large as the 
“doughnut hole” in coverage. Other costs from the complexity are less well measured, but are also 
likely to be large. These include the costs to individuals in the form of the time spent selecting from 
the various plans available and the time that doctors, pharmacists, and other providers must spend 
familiarizing themselves with plan rules, and counseling beneficiaries. At this point, it is too early to 
have reliable estimates of these costs, but the evidence that it is available indicates that these costs 
could be substantial. 
 
The design of the Medicare Modernization Act was highly controversial when it was approved by 
Congress in 2003. As more evidence becomes available concerning its cost and complexity, 
Congress would be wise to reform the benefit to reduce waste and improve coverage.  
 
 
 